img

Global Inactivated Poliovirus Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Inactivated Poliovirus Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Inactivated polio vaccine (IPV) IPV is produced from wild-type poliovirus strains of each serotype that have been inactivated (killed) with formalin.
The global Inactivated Poliovirus Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Inactivated Poliovirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Inactivated Poliovirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Inactivated Poliovirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Inactivated Poliovirus Vaccine include Sanofi, GSK, Serum Institute (Bilthoven Biologicals) and IMBCA, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Inactivated Poliovirus Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Inactivated Poliovirus Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Inactivated Poliovirus Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Inactivated Poliovirus Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Sanofi
GSK
Serum Institute (Bilthoven Biologicals)
IMBCA
By Type
Human Diploid Cell
Monkey Kidney Cell
By Application
Public
Private
Sales by Region
North America
the United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
UK
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Inactivated Poliovirus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Inactivated Poliovirus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Poliovirus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Inactivated Poliovirus Vaccine Definition
1.2 Market by Type
1.2.1 Global Inactivated Poliovirus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Human Diploid Cell
1.2.3 Monkey Kidney Cell
1.3 Market Segment by Application
1.3.1 Global Inactivated Poliovirus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Public
1.3.3 Private
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Inactivated Poliovirus Vaccine Sales
2.1 Global Inactivated Poliovirus Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Inactivated Poliovirus Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Inactivated Poliovirus Vaccine Revenue by Region
2.3.1 Global Inactivated Poliovirus Vaccine Revenue by Region (2018-2024)
2.3.2 Global Inactivated Poliovirus Vaccine Revenue by Region (2024-2034)
2.4 Global Inactivated Poliovirus Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Inactivated Poliovirus Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Inactivated Poliovirus Vaccine Sales Quantity by Region
2.6.1 Global Inactivated Poliovirus Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Inactivated Poliovirus Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Inactivated Poliovirus Vaccine Sales Quantity by Manufacturers
3.1.1 Global Inactivated Poliovirus Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Inactivated Poliovirus Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Inactivated Poliovirus Vaccine Sales in 2022
3.2 Global Inactivated Poliovirus Vaccine Revenue by Manufacturers
3.2.1 Global Inactivated Poliovirus Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Inactivated Poliovirus Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Inactivated Poliovirus Vaccine Revenue in 2022
3.3 Global Inactivated Poliovirus Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Inactivated Poliovirus Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Inactivated Poliovirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Inactivated Poliovirus Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Inactivated Poliovirus Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Inactivated Poliovirus Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Inactivated Poliovirus Vaccine Sales Quantity by Type
4.1.1 Global Inactivated Poliovirus Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Inactivated Poliovirus Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Inactivated Poliovirus Vaccine Revenue by Type
4.2.1 Global Inactivated Poliovirus Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Inactivated Poliovirus Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Inactivated Poliovirus Vaccine Price by Type
4.3.1 Global Inactivated Poliovirus Vaccine Price by Type (2018-2024)
4.3.2 Global Inactivated Poliovirus Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Inactivated Poliovirus Vaccine Sales Quantity by Application
5.1.1 Global Inactivated Poliovirus Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Inactivated Poliovirus Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Inactivated Poliovirus Vaccine Revenue by Application
5.2.1 Global Inactivated Poliovirus Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Inactivated Poliovirus Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Inactivated Poliovirus Vaccine Price by Application
5.3.1 Global Inactivated Poliovirus Vaccine Price by Application (2018-2024)
5.3.2 Global Inactivated Poliovirus Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Inactivated Poliovirus Vaccine Sales by Company
6.1.1 North America Inactivated Poliovirus Vaccine Revenue by Company (2018-2024)
6.1.2 North America Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Inactivated Poliovirus Vaccine Market Size by Type
6.2.1 North America Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Inactivated Poliovirus Vaccine Revenue by Type (2018-2034)
6.3 North America Inactivated Poliovirus Vaccine Market Size by Application
6.3.1 North America Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Inactivated Poliovirus Vaccine Revenue by Application (2018-2034)
6.4 North America Inactivated Poliovirus Vaccine Market Size by Country
6.4.1 North America Inactivated Poliovirus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Inactivated Poliovirus Vaccine Revenue by Country (2018-2034)
6.4.3 North America Inactivated Poliovirus Vaccine Sales Quantity by Country (2018-2034)
6.4.4 the United States
6.4.5 Canada
7 Europe
7.1 Europe Inactivated Poliovirus Vaccine Sales by Company
7.1.1 Europe Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Inactivated Poliovirus Vaccine Revenue by Company (2018-2024)
7.2 Europe Inactivated Poliovirus Vaccine Market Size by Type
7.2.1 Europe Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Inactivated Poliovirus Vaccine Revenue by Type (2018-2034)
7.3 Europe Inactivated Poliovirus Vaccine Market Size by Application
7.3.1 Europe Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Inactivated Poliovirus Vaccine Revenue by Application (2018-2034)
7.4 Europe Inactivated Poliovirus Vaccine Market Size by Country
7.4.1 Europe Inactivated Poliovirus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Inactivated Poliovirus Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Inactivated Poliovirus Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 UK
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Inactivated Poliovirus Vaccine Sales by Company
8.1.1 China Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Inactivated Poliovirus Vaccine Revenue by Company (2018-2024)
8.2 China Inactivated Poliovirus Vaccine Market Size by Type
8.2.1 China Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Inactivated Poliovirus Vaccine Revenue by Type (2018-2034)
8.3 China Inactivated Poliovirus Vaccine Market Size by Application
8.3.1 China Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Inactivated Poliovirus Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Inactivated Poliovirus Vaccine Sales by Company
9.1.1 APAC Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Inactivated Poliovirus Vaccine Revenue by Company (2018-2024)
9.2 APAC Inactivated Poliovirus Vaccine Market Size by Type
9.2.1 APAC Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Inactivated Poliovirus Vaccine Revenue by Type (2018-2034)
9.3 APAC Inactivated Poliovirus Vaccine Market Size by Application
9.3.1 APAC Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Inactivated Poliovirus Vaccine Revenue by Application (2018-2034)
9.4 APAC Inactivated Poliovirus Vaccine Market Size by Region
9.4.1 APAC Inactivated Poliovirus Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Inactivated Poliovirus Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Inactivated Poliovirus Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Inactivated Poliovirus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Sanofi Inactivated Poliovirus Vaccine Products and Services
11.1.5 Sanofi Inactivated Poliovirus Vaccine SWOT Analysis
11.1.6 Sanofi Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Inactivated Poliovirus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 GSK Inactivated Poliovirus Vaccine Products and Services
11.2.5 GSK Inactivated Poliovirus Vaccine SWOT Analysis
11.2.6 GSK Recent Developments
11.3 Serum Institute (Bilthoven Biologicals)
11.3.1 Serum Institute (Bilthoven Biologicals) Company Information
11.3.2 Serum Institute (Bilthoven Biologicals) Overview
11.3.3 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Products and Services
11.3.5 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine SWOT Analysis
11.3.6 Serum Institute (Bilthoven Biologicals) Recent Developments
11.4 IMBCA
11.4.1 IMBCA Company Information
11.4.2 IMBCA Overview
11.4.3 IMBCA Inactivated Poliovirus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 IMBCA Inactivated Poliovirus Vaccine Products and Services
11.4.5 IMBCA Inactivated Poliovirus Vaccine SWOT Analysis
11.4.6 IMBCA Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Inactivated Poliovirus Vaccine Value Chain Analysis
12.2 Inactivated Poliovirus Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Inactivated Poliovirus Vaccine Production Mode & Process
12.4 Inactivated Poliovirus Vaccine Sales and Marketing
12.4.1 Inactivated Poliovirus Vaccine Sales Channels
12.4.2 Inactivated Poliovirus Vaccine Distributors
12.5 Inactivated Poliovirus Vaccine Customers
13 Market Dynamics
13.1 Inactivated Poliovirus Vaccine Industry Trends
13.2 Inactivated Poliovirus Vaccine Market Drivers
13.3 Inactivated Poliovirus Vaccine Market Challenges
13.4 Inactivated Poliovirus Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Inactivated Poliovirus Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Human Diploid Cell
Table 3. Major Manufacturers of Monkey Kidney Cell
Table 4. Global Inactivated Poliovirus Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Inactivated Poliovirus Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Inactivated Poliovirus Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Inactivated Poliovirus Vaccine Revenue Market Share by Region (2018-2024)
Table 8. Global Inactivated Poliovirus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Inactivated Poliovirus Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Inactivated Poliovirus Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Inactivated Poliovirus Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Inactivated Poliovirus Vaccine Sales Market Share by Region (2018-2024)
Table 13. Global Inactivated Poliovirus Vaccine Sales by Region (2024-2034) & (K Units)
Table 14. Global Inactivated Poliovirus Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Inactivated Poliovirus Vaccine Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Inactivated Poliovirus Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Inactivated Poliovirus Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Inactivated Poliovirus Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Inactivated Poliovirus Vaccine Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Inactivated Poliovirus Vaccine, Industry Ranking, 2021 VS 2022
Table 21. Global Inactivated Poliovirus Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Inactivated Poliovirus Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Poliovirus Vaccine as of 2022)
Table 23. Global Key Manufacturers of Inactivated Poliovirus Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Inactivated Poliovirus Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Inactivated Poliovirus Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Inactivated Poliovirus Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Inactivated Poliovirus Vaccine Sales Quantity Share by Type (2018-2024)
Table 30. Global Inactivated Poliovirus Vaccine Sales Quantity Share by Type (2024-2034)
Table 31. Global Inactivated Poliovirus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Inactivated Poliovirus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Inactivated Poliovirus Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Inactivated Poliovirus Vaccine Revenue Share by Type (2024-2034)
Table 35. Inactivated Poliovirus Vaccine Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Inactivated Poliovirus Vaccine Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Inactivated Poliovirus Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Inactivated Poliovirus Vaccine Sales Quantity Share by Application (2018-2024)
Table 40. Global Inactivated Poliovirus Vaccine Sales Quantity Share by Application (2024-2034)
Table 41. Global Inactivated Poliovirus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Inactivated Poliovirus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Inactivated Poliovirus Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Inactivated Poliovirus Vaccine Revenue Share by Application (2024-2034)
Table 45. Inactivated Poliovirus Vaccine Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Inactivated Poliovirus Vaccine Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Inactivated Poliovirus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Inactivated Poliovirus Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Inactivated Poliovirus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Inactivated Poliovirus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Inactivated Poliovirus Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Inactivated Poliovirus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Inactivated Poliovirus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Inactivated Poliovirus Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Inactivated Poliovirus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Inactivated Poliovirus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Inactivated Poliovirus Vaccine Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Inactivated Poliovirus Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Inactivated Poliovirus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Inactivated Poliovirus Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Inactivated Poliovirus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Inactivated Poliovirus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Inactivated Poliovirus Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Inactivated Poliovirus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Inactivated Poliovirus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Inactivated Poliovirus Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Inactivated Poliovirus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Inactivated Poliovirus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Inactivated Poliovirus Vaccine Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Inactivated Poliovirus Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Inactivated Poliovirus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Inactivated Poliovirus Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Inactivated Poliovirus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Inactivated Poliovirus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Inactivated Poliovirus Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Inactivated Poliovirus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Inactivated Poliovirus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Inactivated Poliovirus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Inactivated Poliovirus Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Inactivated Poliovirus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Inactivated Poliovirus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Inactivated Poliovirus Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Inactivated Poliovirus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Inactivated Poliovirus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Inactivated Poliovirus Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Inactivated Poliovirus Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Inactivated Poliovirus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Inactivated Poliovirus Vaccine Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Inactivated Poliovirus Vaccine Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Sanofi Company Information
Table 118. Sanofi Description and Overview
Table 119. Sanofi Inactivated Poliovirus Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Sanofi Inactivated Poliovirus Vaccine Product and Services
Table 121. Sanofi Inactivated Poliovirus Vaccine SWOT Analysis
Table 122. Sanofi Recent Developments
Table 123. GSK Company Information
Table 124. GSK Description and Overview
Table 125. GSK Inactivated Poliovirus Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. GSK Inactivated Poliovirus Vaccine Product and Services
Table 127. GSK Inactivated Poliovirus Vaccine SWOT Analysis
Table 128. GSK Recent Developments
Table 129. Serum Institute (Bilthoven Biologicals) Company Information
Table 130. Serum Institute (Bilthoven Biologicals) Description and Overview
Table 131. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Product and Services
Table 133. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine SWOT Analysis
Table 134. Serum Institute (Bilthoven Biologicals) Recent Developments
Table 135. IMBCA Company Information
Table 136. IMBCA Description and Overview
Table 137. IMBCA Inactivated Poliovirus Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. IMBCA Inactivated Poliovirus Vaccine Product and Services
Table 139. IMBCA Inactivated Poliovirus Vaccine SWOT Analysis
Table 140. IMBCA Recent Developments
Table 141. Key Raw Materials Lists
Table 142. Raw Materials Key Suppliers Lists
Table 143. Inactivated Poliovirus Vaccine Distributors List
Table 144. Inactivated Poliovirus Vaccine Customers List
Table 145. Inactivated Poliovirus Vaccine Market Trends
Table 146. Inactivated Poliovirus Vaccine Market Drivers
Table 147. Inactivated Poliovirus Vaccine Market Challenges
Table 148. Inactivated Poliovirus Vaccine Market Restraints
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Inactivated Poliovirus Vaccine Product Picture
Figure 2. Global Inactivated Poliovirus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Inactivated Poliovirus Vaccine Market Share by Type in 2022 & 2034
Figure 4. Human Diploid Cell Product Picture
Figure 5. Monkey Kidney Cell Product Picture
Figure 6. Global Inactivated Poliovirus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Inactivated Poliovirus Vaccine Market Share by Application in 2022 & 2034
Figure 8. Public
Figure 9. Private
Figure 10. Inactivated Poliovirus Vaccine Report Years Considered
Figure 11. Global Inactivated Poliovirus Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Inactivated Poliovirus Vaccine Revenue 2018-2034 (US$ Million)
Figure 13. Global Inactivated Poliovirus Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 14. Global Inactivated Poliovirus Vaccine Sales Quantity 2018-2034 (K Units)
Figure 15. Global Inactivated Poliovirus Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 16. Global Inactivated Poliovirus Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 17. North America Inactivated Poliovirus Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 18. North America Inactivated Poliovirus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Inactivated Poliovirus Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. Europe Inactivated Poliovirus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Inactivated Poliovirus Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. China Inactivated Poliovirus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. APAC Inactivated Poliovirus Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. APAC Inactivated Poliovirus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Inactivated Poliovirus Vaccine Sales Quantity in 2022
Figure 28. The Top 10 and Top 5 Players Market Share by Inactivated Poliovirus Vaccine Revenue in 2022
Figure 29. Inactivated Poliovirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 31. Global Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
Figure 32. Global Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 33. Global Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
Figure 34. North America Inactivated Poliovirus Vaccine Revenue Market Share by Company in 2022
Figure 35. North America Inactivated Poliovirus Vaccine Sales Quantity Market Share by Company in 2022
Figure 36. North America Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 37. North America Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
Figure 38. North America Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 39. North America Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
Figure 40. North America Inactivated Poliovirus Vaccine Revenue Share by Country (2018-2034)
Figure 41. North America Inactivated Poliovirus Vaccine Sales Quantity Share by Country (2018-2034)
Figure 42. the United States Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Inactivated Poliovirus Vaccine Sales Quantity Market Share by Company in 2022
Figure 45. Europe Inactivated Poliovirus Vaccine Revenue Market Share by Company in 2022
Figure 46. Europe Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 47. Europe Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
Figure 48. Europe Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 49. Europe Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
Figure 50. Europe Inactivated Poliovirus Vaccine Revenue Share by Country (2018-2034)
Figure 51. Europe Inactivated Poliovirus Vaccine Sales Quantity Share by Country (2018-2034)
Figure 52. Germany Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. France Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. UK Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. China Inactivated Poliovirus Vaccine Sales Quantity Market Share by Company in 2022
Figure 58. China Inactivated Poliovirus Vaccine Revenue Market Share by Company in 2022
Figure 59. China Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 60. China Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
Figure 61. China Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 62. China Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
Figure 63. APAC Inactivated Poliovirus Vaccine Sales Quantity Market Share by Company in 2022
Figure 64. APAC Inactivated Poliovirus Vaccine Revenue Market Share by Company in 2022
Figure 65. APAC Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 66. APAC Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
Figure 67. APAC Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 68. APAC Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
Figure 69. APAC Inactivated Poliovirus Vaccine Revenue Share by Region (2018-2034)
Figure 70. APAC Inactivated Poliovirus Vaccine Sales Quantity Share by Region (2018-2034)
Figure 71. Japan Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 72. South Korea Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 73. China Taiwan Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. Southeast Asia Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. India Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity Market Share by Company in 2022
Figure 77. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 79. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 81. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Sales Quantity Share by Country (2018-2034)
Figure 83. Middle East, Africa and Latin America Inactivated Poliovirus Vaccine Revenue Share by Country (2018-2034)
Figure 84. Brazil Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 85. Mexico Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 86. Turkey Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Israel Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. GCC Countries Inactivated Poliovirus Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. Inactivated Poliovirus Vaccine Value Chain
Figure 90. Inactivated Poliovirus Vaccine Production Process
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed